Patent classifications
C
CHEMISTRY; METALLURGY
Load children
C12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Load children
C12N
MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
Load children
C12N2710/00041
Use of virus, viral particle or viral elements as a vector
Load children Filter patents View analytics View as hierarchy Open in page
C12N2710/00044
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
Filter patents View analytics View as hierarchy Open in page

C12N2710/00044

Oncolytic adenoviruses coding for bi-specific antibodies
11485791 · 2022-11-01 · ·

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to an oncolytic adenoviral vector encoding a bispecific monoclonal antibody. Furthermore, the present invention relates to methods and uses utilizing the oncolytic adenoviral vectors, also together with adoptive cell therapies.

Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
20230272108 · 2023-08-31 ·

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to an oncolytic adenoviral vector encoding a bispecific monoclonal antibody. Furthermore, the present invention relates to methods and uses utilizing the oncolytic adenoviral vectors, also together with adoptive cell therapies.

Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
20180072809 · 2018-03-15 ·

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to an oncolytic adenoviral vector encoding a bispecific monoclonal antibody. Furthermore, the present invention relates to methods and uses utilizing the oncolytic adenoviral vectors, also together with adoptive cell therapies.